A recent study revealed the effectiveness of Whole Genome Sequencing over methylation-based methods. Based in Irving, Texas, Caris Life Sciences® (NASDAQ: CAI), a top patient-focused AI TechBio company specializing in precision medicine, shared these results on March 31, 2026.